Susanne Ramm

ORCID: 0000-0003-1108-5620 · 2 papers in corpus

preprint 2026

Dienogest interrupts the chemokine signalling axis in endometriotic lesions with resistant signatures providing novel opportunities for personalised treatment.

·doi:10.21203/rs.3.rs-8096027/v1

Abstract Progestins are important first line and adjuvant medications for endometriosis, yet their efficacy varies among patients. Dienogest (DNG), a 4th generation progestin, is one of the most prescribed and successful progestins, althou…

2024

A new method for network bioinformatics identifies novel drug targets for mucinous ovarian carcinoma.

NAR genomics and bioinformatics ·doi:10.1093/nargab/lqae096

Mucinous ovarian carcinoma (MOC) is a subtype of ovarian cancer that is distinct from all other ovarian cancer subtypes and currently has no targeted therapies. To identify novel therapeutic targets, we developed and applied a new method of…